Drugs A - Z
Generic Name: chondroitin
CategoryHerbs & Supplements
ACS4-ACS6, ADAMTS7B, aggrecan, agrin, biglycan, biostat, CDS, chondroitin sulfate A, chondroitin sulfate C, chondroitin sulfate proteoglycan, chondroitin sulfates, chondroitin sulfuric acid, chondroitin sulphate, chondroitin sulphate A sodium, chondroitin-4-sulfate, chondroitin-6-sulfate, chondroitinase ABC, chondroprotective agents, chondrosine, chonsurid, CHST11, condroitin, Condrosulf®, Condrosulf 400®, CS, CS/DS, CSA, CSC, CSPG D-galactosamine, decorin, dentin sialoprotein, DexSol®, D-glucuronic acid, disease modifying osteoarthritis drugs, DMOAD, extended chondroitin sulfate/dermatan, fucosylated chondroitin sulfate, GAG, galacotosaminoglucuronoglycan sulfate (Matrix®), glucosamine hydrochloride, glucosamine salts, glucosamine sulfate, glucosaminoglycan, Matrix®, neurocan, neuroglycan C, NGC, Optisol®, perineuronal nets, PNs, sodium chondroitin sulfate 0.2%, sodium chondroitin, Structum®, sulphate, symptomatic slow acting drug in osteoarthritis type XV, Syndecan, SYSADOA type XV, Uropol®-S, Viscoat®.
Chondroitin was first extracted and purified in the 1960s. It is currently manufactured from natural sources (shark/beef cartilage or bovine trachea) or by synthetic means. The consensus of expert and industry opinions supports the use of chondroitin and its common partner agent, glucosamine, for improving symptoms and stopping (or possibly reversing) the degenerative process of osteoarthritis.
EvidenceDISCLAIMER: These uses have been tested in humans or animals. Safety and effectiveness have not always been proven. Some of these conditions are potentially serious, and should be evaluated by a qualified healthcare provider.
Multiple controlled clinical trials since the 1980s have examined the use of oral chondroitin in patients with osteoarthritis of the knee and other locations (spine, hips, finger joints). Most of these studies have reported significant benefits in terms of symptoms (such as pain), function (such as mobility), and reduced medication requirements (such as anti-inflammatories). However, most studies have been brief (six month duration) with methodological weaknesses. Despite these weaknesses and potential for bias in the available results, the weight of scientific evidence points to a beneficial effect when chondroitin is used for 6-24 months. Longer-term effects are not clear. Early studies of chondroitin applied to the skin have also been conducted.
Chondroitin is frequently used with glucosamine. Glucosamine has independently been demonstrated to benefit patients with osteoarthritis (particularly of the knee). It remains unclear if there is added benefit of using these two agents together compared to using either alone.
Several studies have shown promise for using chondroitin for interstitial cystitis, which is a chronic inflammation of the bladder. Chondroitin sulfate may also be helpful in patients with overactive bladder or unstable bladder control. Additional evidence is necessary before a firm conclusion can be drawn.
Coronary artery disease (secondary prevention):
Several studies in the early 1970s assessed the use of oral chondroitin for the prevention of subsequent coronary events in patients with a history of heart disease or heart attack. Although favorable results were reported, due to methodological weaknesses in this research and the widespread current availability of more proven drug therapies for patients in this setting, a recommendation cannot be made in this area.
There is preliminary research administering intravesicular chondroitin in patients diagnosed with interstitial cystitis. Additional evidence is necessary before a firm conclusion can be drawn.
Iron absorption enhancement:
Early research suggests that taking chondroitin with iron may enhance iron absorption in healthy individuals. It is unclear whether taking chondroitin would help patients with iron deficiencies absorb more iron. More research needs to be done in this area before a strong recommendation can be made.
Chondroitin is sometimes used as a component of eye solutions used for keratoconjunctivitis, corneal preservation, and intraocular pressure. These solutions should only be used under the supervision of an ophthalmologist. Additional study is needed in this area.
Early study suggests that chondroitin may help treat psoriasis. Well-designed clinical trials are needed to confirm these results.
Muscle soreness (delayed onset):
Chondroitin was thought to be beneficial for delayed onset muscle soreness because chondroitin sulfate is often used as an anti-inflammatory and pain reliever for osteoarthritis. However, early research does not support this use. More research is needed in this area to confirm these results.
TraditionWARNING: DISCLAIMER: The below uses are based on tradition, scientific theories, or limited research. They often have not been thoroughly tested in humans, and safety and effectiveness have not always been proven. Some of these conditions are potentially serious, and should be evaluated by a qualified healthcare provider. There may be other proposed uses that are not listed below.
Aging, allergies, Alzheimer's disease, analgesic, angina (chest pain), anticoagulant (blood thinner), anti-inflammatory, antioxidant, antithrombotic, atherosclerosis, bone healing, breast cancer, cardiovascular health, chronic venous ulcers, deep intra-osseous defects, gonarthrosis, gum disease, headaches, heart attack (treatment and prevention), high cholesterol, HIV/AIDS, hyperglycemia/diabetes, iron deficiency anemia, joint pain, joint problems (cartilage repair, disc degeneration, synovial fluid productions), kidney stones, leukemia, malaria, nerve regeneration, osteoporosis, premature birth prevention, respiratory ailments, rheumatoid arthritis, snoring, soft tissue injury (torn ligaments and tendons), spinal cord injury, sports injuries, venous leg ulcers, wound healing.
Adult (18 years and older)
Doses of 200-400 milligrams by mouth twice to three times daily, or 800-1,200 milligrams once daily have been used in studies. Higher doses (up to 2,000 milligrams) appear to have similar efficacy. In the treatment of osteoarthritis, full effects may take several weeks to occur.
It is not clear what dose is optimal when used in combination with glucosamine or whether the combination is as effective as or more effective than either agent alone.
For osteoarthritis, 50-100 milligrams as a single daily injection or divided into two daily injections has been used. Medical supervision is recommended.
Children (younger than 18 years)
There is no proven effective dose for chondroitin in children.
SafetyDISCLAIMER: Many complementary techniques are practiced by healthcare professionals with formal training, in accordance with the standards of national organizations. However, this is not universally the case, and adverse effects are possible. Due to limited research, in some cases only limited safety information is available.
Use cautiously if allergic or hypersensitive to chondroitin sulfate products. Use cautiously in patients with shellfish allergy, due to the possibility of allergic reaction. Hives, rash, sun skin sensitivity, and worsening of previously well-controlled asthma have been reported.
Side Effects and Warnings
Chondroitin sulfate appears to be well tolerated for up to three years.
Adverse effects that have been rarely reported or are theoretical include: headache, motor uneasiness, euphoria, hives, rash, photosensitivity, hair loss, breathing difficulties, subjective tightness in the throat or chest, exacerbation of previously well-controlled asthma, chest pain, elevated blood pressure, lower extremity edema, gastrointestinal pain/dyspepsia, nausea, diarrhea, constipation, transaminitis, increased risk of bleeding (theoretical), bone marrow suppression (animal research), and eyelid edema.
Avoid in individuals with prostate cancer, or at increased risk for prostate cancer, due to a risk of increased spread or recurrence of prostate cancer.
Pregnancy and Breastfeeding
Interactions with Drugs
In theory, chondroitin may increase the risk of bleeding when taken with drugs that increase the risk of bleeding. Some examples include aspirin, anticoagulants ("blood thinners") such as warfarin (Coumadin®) or heparin, anti-platelet drugs such as clopidogrel (Plavix®), and non-steroidal anti-inflammatory drugs such as ibuprofen (Motrin®, Advil®) or naproxen (Naprosyn®, Aleve®).
Use cautiously with hyaluronidase or agents with hydrophilic (attraction to water) properties. Consult with a qualified healthcare professional, including a pharmacist, to check for interactions.
Also use cautiously when combining chondroitin with other agents that may cause sun sensitivity, as chondroitin may increase sun sensitivity.
Interactions with Herbs and Dietary Supplements
In theory, chondroitin may increase the risk of bleeding when taken with herbs and supplements that are believed to increase the risk of bleeding. Multiple cases of bleeding have been reported with the use of Ginkgo biloba, and fewer cases with garlic and saw palmetto. Numerous other agents may theoretically increase the risk of bleeding, although this has not been proven in most cases.
Based on preliminary data, chondroitin may increase iron absorption. It may also interact with or alter concentrations of calcium, camphor, glucosamine, manganese, peppermint oil, and shark cartilage.
Use cautiously with herbs or supplements with hydrophilic (attraction to water) properties. Consult with a qualified healthcare professional, including a pharmacist, to check for interactions. Also use cautiously when combining chondroitin with other agents that may cause sun sensitivity, as chondroitin may increase sun sensitivity.
This information is based on a professional level monograph edited and peer-reviewed by contributors to the Natural Standard Research Collaboration (www.naturalstandard.com): Ethan Basch, MD, MPhil (Memorial Sloan-Kettering Cancer Center); Heather Boon B.Sc.Phm, PhD (University of Toronto); Julie Conquer, PhD (RGB Consulting); Dawn Costa, BA, BS (Natural Standard Research Collaboration); Renn Crichlow, MD (Massachusetts General Hospital); Nicole Giese, MS (Natural Standard Research Collaboration); Brad Jacobs MD, MPH (University of California-San Francisco); Mitchell Knutson, MPH (Harvard School of Public Health), Tamara Milkin, PharmD (Northeastern University); Gavin J. Putzer, MD, MPH (Harvard School of Public Health), Mitchell Knutson, MPH (Harvard School of Public Health); Gavin J. Putzer, MD, MPH (Harvard School of Public Health); Erica Seamon, PharmD (Natural Standard Research Collaboration); Eric Seeley MD (University of California-San Francisco); Shaina Tanguay-Colucci, BS (Natural Standard Research Collaboration); Catherine Ulbricht, PharmD, MBA[c] (Massachusetts General Hospital); Minney Varghese, BS (Northeastern University); Wendy Weissner, BA (Natural Standard Research Collaboration).
BibliographyDISCLAIMER: Natural Standard developed the above evidence-based information based on a thorough systematic review of the available scientific articles. For comprehensive information about alternative and complementary therapies on the professional level, go to www.naturalstandard.com. Selected references are listed below.
Bjordal JM, Klovning A, Ljunggren AE, et al. Short-term efficacy of pharmacotherapeutic interventions in osteoarthritic knee pain: A meta-analysis of randomised placebo-controlled trials. Eur J Pain 2007;11(2):125-138.
Bourgeois P, Chales G, Dehais J, et al. Efficacy and tolerability of chondroitin sulfate 1200 mg/day vs chondroitin sulfate 3 x 400 mg/day vs placebo. Osteoarthritis Cartilage 1998;6 Suppl A:25-30.
Braun WA, Flynn MG, Armstrong WJ, et al. The effects of chondroitin sulfate supplementation on indices of muscle damage induced by eccentric arm exercise. J Sports Med Phys Fitness 2005;45(4):553-560.
Clegg DO, Reda DJ, Harris CL, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 2-23-2006;354(8):795-808.
Cohen M, Wolfe R, Mai T, et al. A randomized, double blind, placebo controlled trial of a topical cream containing glucosamine sulfate, chondroitin sulfate, and camphor for osteoarthritis of the knee. J Rheumatol 2003;30(3):523-528.
Felson DT. Glucosamine and chondroitin sulfate in knee osteoarthritis: where now? Nat Clin Pract Rheumatol 2006;2(7):356-357.
Leffler CT, Philippi AF, Leffler SG, et al. Glucosamine, chondroitin, and manganese ascorbate for degenerative joint disease of the knee or low back: a randomized, double-blind, placebo-controlled pilot study. Mil Med 1999;164(2):85-91.
Mazieres B, Hucher M, Zaim M, et al. Effect of chondroitin sulphate in symptomatic knee osteoarthritis: a multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis 2007;66(5):639-645.
McAlindon TE, LaValley MP, Gulin JP, et al. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA 2000;283(11):1469-1475.
Michel BA, Stucki G, Frey D, et al. Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial. Arthritis Rheum 2005 Mar;52(3):779-86.
Richy F, Bruyere O, Ethgen O, et al. Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis. Arch Intern Med 2003;163(13):1514-1522.
Rozenfeld V, Crain JL, Callahan AK. Possible augmentation of warfarin effect by glucosamine-chondroitin. Am J Health Syst Pharm 2004;61(3):306-307.
Tallia AF, Cardone DA. Asthma exacerbation associated with glucosamine-chondroitin supplement. J Am Board Fam Pract 2002;15(6):481-484.
Towheed TE, Anastassiades TP. Glucosamine and chondroitin for treating symptoms of osteoarthritis: evidence is widely touted but incomplete. JAMA 2000;283(11):1483-1484.
Uebelhart D, Malaise M, Marcolongo R, et al. Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a one-year, randomized, double-blind, multicenter study versus placebo. Osteoarthritis Cartilage 2004;12(4):269-276.